Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Stanley Glasser

Pulmonary Disease Springfield, MA Medical Doctor

NPI 1487694386 CMS profile 249251

222 Carew Street, Valley Pulmonary & Medical Assoc 2Nd Floor, Springfield, MA 01104

Open in the dashboard

General payments

$4,681

235 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Stanley Glasser of Springfield, MA is reported in the CMS Open Payments database as having received $4,681 across 235 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $384 22
2020 General $704 31
2019 General $3,593 182

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stanley Glasser
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Stanley Glasser were reported at $0. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Stanley Glasser Pulmonary Disease median Middle half National median
2019 $3,593 $377 $109–$1,340 $163
2020 $704 $230 $56–$907 $114
2021 $384 $269 $68–$1,072 $132
2022 $0 $390 $100–$1,457 $149
2023 $0 $419 $114–$1,659 $160
2024 $0 $476 $123–$1,818 $164
2025 $0 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Pfizer Inc. $535 40 payments
  2. Amgen Inc. $486 20 payments
  3. GlaxoSmithKline, LLC. $469 30 payments
  4. Teva Pharmaceuticals USA, Inc. $435 14 payments
  5. AbbVie, Inc. $294 17 payments
  6. Allergan Inc. $281 15 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $246 11 payments
  8. AstraZeneca Pharmaceuticals LP $220 12 payments
  9. Genzyme Corporation $217 7 payments
  10. Lilly USA, LLC $190 9 payments
  11. Other $1,308 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $4,660 232 payments
  2. Education $21 3 payments
Products named General payments · program years 2019–2021
  1. Ajovy $425 11 payments
  2. EUCRISA $339 17 payments
  3. TRELEGY ELLIPTA $333 16 payments
  4. Prolia $317 12 payments
  5. OFEV $280 12 payments
  6. DUPIXENT $214 7 payments
  7. Repatha $210 10 payments
  8. CREON $200 11 payments
  9. SYMBICORT $170 9 payments
  10. Arikayce $169 3 payments
  11. Other $3,106 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

235 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record